行情

JAZZ

JAZZ

爵士制药
NASDAQ

实时行情|Nasdaq Last Sale

130.18
+1.08
+0.84%
交易中 14:39 09/22 EDT
开盘
129.97
昨收
129.10
最高
131.54
最低
128.43
成交量
24.20万
成交额
--
52周最高
189.00
52周最低
127.80
市值
79.88亿
市盈率(TTM)
137.87
分时
5日
1月
3月
1年
5年
Grove 的收购推动了公司的发展
Since its initial public offering (IPO) in June, Grove Inc. (NASDAQ: GRVI) has embarked on a journey that will establish it as a leading manufacturer of hemp-derived CBD-based products as well as nutritional supplements.
Benzinga · 5小时前
Axsome (AXSM) 开始对 AXS-12 进行晚期睡眠障碍研究
Zacks.com · 5天前
Jazz Pharmaceuticals 于 2021 年 10 月 13 日宣布 Xywav 投资者网络广播
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that the company will host a webcast on Wednesday, October 13, 2021 at 4:30 p.m. ET / 9:30 p.m. IST to provide an update on
Benzinga · 09/13 20:16
Jazz Pharmaceuticals 于 2021 年 10 月 13 日宣布 Xywav ®(钙、镁、钾和羟丁酸钠)投资者网络广播
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will host a webcast on Wednesday, October 13, 2021 at 4:30 p.m. ET / 9:30 p.m. IST to provide an update on Xywav® (calcium, magnesium, potassium and sodium oxybates), the first and on...
PR Newswire · 09/13 20:15
CBD 股票准备好再次上涨了吗? (爵士乐、YCBD、NEPT、CVSI、MJNA、ALST)
WallStreetPR · 09/09 11:07
Jazz Pharmaceuticals 将参加即将举行的 9 月投资者会议
/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will participate in the following upcoming virtual investor conferences:
PR Newswire - PRF · 09/08 20:15
到 2025 年,三种主要药用大麻产品的销售额将达到 18 亿欧元
By Prohibition Partners Combined sales of the three most lucrative cannabis pharmaceuticals products - Epidiolex®, Dronabinol and Sativex® - are set to reach €1.8 billion by 2025, according to a new report. 
Benzinga · 09/08 15:57
爵士(JAZZ)自上次财报以来下跌 14.1%:能否反弹?
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks · 09/02 15:31
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解JAZZ最新的财务预测,通过JAZZ每股收益,每股净资产,每股现金流等数据分析爵士制药近期的经营情况,然后做出明智的投资选择。
分析师评级

17位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测JAZZ价格均价为207.82,最高价位250.00,最低价为176.00。
EPS
机构持股
总机构数: 711
机构持股: 6,346.30万
持股比例: 103.42%
总股本: 6,136.40万
类型机构数股数
增持
196
586.55万
建仓
51
173.40万
减持
176
407.65万
平仓
141
197.83万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
制药
+0.06%
制药与医学研究
+0.23%
高管信息
Chairman/Chief Executive Officer/Director
Bruce Cozadd
President
Daniel Swisher
Chief Financial Officer/Executive Vice President
Renee Gala
Chief Operating Officer/Executive Vice President/Managing Director
Christopher Tovey
Executive Vice President/General Manager
Kimberly Sablich
Executive Vice President
Robert Iannone
Senior Vice President
Finbar Larkin
Senior Vice President
Neena Patil
Senior Vice President
Samantha Pearce
Chief Accounting Officer/Vice President - Finance
Patricia Carr
Lead Director/Independent Director
Rick Winningham
Independent Director
Jennifer Cook
Independent Director
Patrick Enright
Independent Director
Peter Gray
Independent Director
Heather Mcsharry
Independent Director
Seamus Mulligan
Independent Director
Kenneth O'Keefe
Independent Director
Anne O'Riordan
Independent Director
Norbert Riedel
Independent Director
Mark Smith
Independent Director
Catherine Sohn
暂无数据
JAZZ 简况
Jazz Pharmaceuticals Public Limited Company是一家生物制药公司。该公司致力于开发和商业化解决未满足的医疗需求的产品。该公司拥有针对睡眠和血液学/肿瘤学领域的多元化产品与候选产品组合。该公司的主导市场产品包括治疗发作性嗜睡病患者猝倒和日间过度嗜睡(EDS)的Xyrem(羟丁酸钠口服溶液)、治疗急性淋巴细胞白血病(ALL)的Erwinaze和治疗重度肝静脉闭塞性疾病(VOD)的Defitelio(去纤苷)。该公司的其他候选产品包括治疗发作性嗜睡病中的EDS与阻塞性睡眠呼吸暂停(OSA)患者的EDS的JZP-110,以及治疗发作性嗜睡病中的EDS的JZP-386。

微牛提供Jazz Pharmaceuticals PLC(NASDAQ-JAZZ)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的JAZZ股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易JAZZ股票基本功能。